HIMS
Hims & Hers Health, Inc.
NYSE · Healthcare · Medical - Equipment & Services · US
$27.55
−0.97%Sep 4, 2026, 16:01 UTC
A class action lawsuit was filed against Hims & Hers Health, Inc. alleging that the company made materially false and misleading statements during the Class Period, causing investor harm.
Source:Sep 3, 2026, 20:00 UTC
A class action lawsuit was filed against Hims & Hers Health, Inc. on behalf of investors who purchased its securities between August 4, 2025 and July 29, 2026.
Aug 31, 2026, 18:56 UTC
Hims & Hers began offering branded GLP-1 weight-loss drugs and men's health treatments in Australia on Monday, expanding its international business.
Aug 24, 2026, 17:00 UTC
BBB National Programs' National Advertising Division ruled on a challenge by Kenvue Inc., finding that Hims & Hers Health, Inc. had support for its comparative efficacy claim but recommending modification or discontinuance of other advertising claims.
Source:Aug 24, 2026, 16:45 UTC
Hims & Hers Health received a warning from Visa due to excessive customer disputes over its weight-loss drug subscription service, leading to its inclusion in Visa's Acquirer Monitoring Program (VAMP).
Aug 24, 2026, 15:15 UTC
The U.S. Federal Trade Commission, along with the Utah Division of Consumer Protection and the California Attorney General, filed a complaint in the Northern District of California against Hims & Hers Health, Inc., alleging violations of privacy and consumer protection laws related to sharing sensitive health information and billing practices.
Source:Aug 12, 2026, 19:02 UTC
Following the FTC lawsuit news, Hims & Hers Health, Inc.'s stock price fell over 14%.
Source:Aug 11, 2026, 13:45 UTC
Hims & Hers Health announced plans to enter the peptide market within the year to capture demand in the rapidly growing healthcare market.
Source:Aug 11, 2026, 11:21 UTC
Hims & Hers Health's shares fell nearly 7% in premarket trading on Tuesday, reflecting investor concerns over shrinking profit margins.
Source:Aug 10, 2026, 20:05 UTC
Hims & Hers Health, Inc. announced its financial results for the second quarter ended June 30, 2026.
Aug 7, 2026, 19:07 UTC
Bragar Eagel & Squire, P.C. announced an investigation into Hims & Hers Health, Inc. for potential federal securities law violations, following an FTC action on July 29, 2026.
Source:Jul 24, 2026, 03:40 UTC
An FDA advisory panel voted to recommend easing restrictions on four peptides (BPC-157, KPV, TB-500, MOTS-C), potentially expanding the market for telehealth firms like Hims & Hers Health.
Jul 17, 2026, 20:17 UTC
Hims & Hers Health announced that Chief Accounting Officer Irene Becklund will depart the company effective October 9, 2026.
Source:Jul 8, 2026, 12:34 UTC
Hims & Hers Health acquired Eucalyptus for $1.15 billion, adding 850,000 customers and approximately $450 million of ARR across eight international markets.
Source:Jul 8, 2026, 12:34 UTC
Hims & Hers Health secured a $400 million receivables facility from JPMorgan to improve financial flexibility.
Source:Jul 1, 2026, 18:15 UTC
Hims & Hers Health shares surged 9% on Wednesday.
Source:Jul 1, 2026, 00:00 UTC
Hims & Hers Health, Inc. entered into a Master Receivables Purchase Agreement with JPMorgan Chase Bank, N.A., establishing a $400 million uncommitted facility for the purchase of eligible receivables, and amended its existing revolving credit agreement to permit this transaction.
Jun 24, 2026, 23:59 UTC
Hims & Hers Health completed its acquisition of Eucalyptus on June 2.
Source:Jun 4, 2026, 13:00 UTC
Hims & Hers Health appointed Dr. Anant Vinjamoori as Chief Medical Officer of the Hims brand.
Source:Jun 2, 2026, 09:00 UTC
Hims & Hers Health, Inc. completed its acquisition of Eucalyptus, the parent company of Juniper, expanding its weight management care in Germany.
Jun 2, 2026, 00:00 UTC
Hims & Hers Health, Inc. amended its existing revolving credit facility on May 29, 2026, to facilitate its acquisition of Eucalyptus, increasing allowable investments in non-loan party subsidiaries and adding joinder obligations for material foreign subsidiaries.
May 21, 2026, 00:00 UTC
Hims & Hers Health, Inc. issued $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032, comprising $350.0 million initial principal and a $52.5 million option to purchase additional notes, with conversion into Class A Common Stock at an initial rate of 33.8590 shares per $1,000 principal amount.